Evidence map›Paper›PMID 41898689›Full record

ArticleInternational journal of molecular sciences2026

A Cytokine-Related Gene Signature for Pan-Cancer Prognostic Stratification and Malignant Phenotype Characterization.

Shih-Chieh Chen, Kai-Fu Chang, Chien-Cheng Chao, Chung-Hsien Lin, Chih-Hsuan Chang, Ching-Chung Ko, Hui-Ru Lin, Chi-Jen Wu, Chien-Han Yuan, Sachin Kumar and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shih-Chieh ChenDepartment of Internal Medicine, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.
Kai-Fu ChangMedical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.
Chien-Cheng ChaoMedical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.
Chung-Hsien LinMedical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.
Chih-Hsuan ChangMedical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.
Ching-Chung KoDepartment of Medical Imaging, Chi-Mei Medical Center, Tainan 71004, Taiwan.ORCID 0000-0003-0721-9606
Hui-Ru LinInstitute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan.ORCID 0009-0006-8072-2485
Chi-Jen WuNursing Department, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.ORCID 0000-0003-2160-8472
Chien-Han YuanMedical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.ORCID 0000-0001-5939-6781
Sachin KumarPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0009-0009-5321-8197
Dahlak Daniel SolomonPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Do Thi Minh XuanFaculty of Pharmacy, Van Lang University, 69/68 Dang Thuy Tram Street, Binh Loi Trung Ward, Ho Chi Minh City 70000, Vietnam.
Neethu PalekkodePhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0009-0008-1269-2397
Ayman FathimaGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Junanda WaikhomPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Chih-Yang WangPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-4137-5074
Yung-Kuo LeeMedical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.ORCID 0000-0003-1638-8049
Hui-Pu LiuDepartment of General Surgery, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan.ORCID 0000-0002-8673-5440

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokines are central regulators of inflammation and immune responses within the tumor microenvironment and have been implicated in cancer progression and prognosis. However, the prognostic value of coordinated cytokine-related transcriptional programs across cancer types has not been systematically explored. Pan-cancer transcriptomic and clinical data were analyzed to construct a cytokine-related prognostic signature using least absolute shrinkage and selection operator (LASSO) Cox regression. Patients were stratified into high-risk and low-risk groups based on the derived risk score. Prognostic performance was evaluated in training and test cohorts, and biological relevance was assessed through survival analyses and pathway-level investigations. A 16-gene cytokine-related signature was established that consistently stratified patients into distinct prognostic groups across multiple cancer types. High cytokine-related risk scores were significantly associated with unfavorable survival outcomes and were linked to enhanced cell cycle activity, epithelial-mesenchymal transition, and extracellular matrix remodeling. Integration of the risk score with clinical variables improved individualized survival prediction. Immunohistochemical analyses further confirmed increased protein expression of representative risk-associated genes, including pannexin 1 (PANX1) and FERM domain containing 8 (FRMD8), in multiple tumor tissues compared with corresponding normal tissues. The cytokine-related prognostic signature captures key inflammatory and immune-related programs underlying tumor aggressiveness and provides a robust tool for pan-cancer risk stratification with potential clinical utility.

Indexed as

Biomarkers, TumorCytokinesNeoplasmsTranscriptomeFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPhenotypePrognosisTumor MicroenvironmentBiomarkers, TumorCytokinescytokinesinflammationpan-cancerprognostic signaturesurvival analysistumor microenvironment

Identifiers

PMID41898689
PMCPMC13027118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.